Title (en)

METHODS OF MODIFYING INSULIN SIGNALING USING BILIVERDIN REDUCTASE (BVR) AND BVR DERIVED PEPTIDES

Title (de)

VERFAHREN ZUR MODIFIKATION EINER INSULINSIGNALÜBERTRAGUNG MITTELS BILIVERDINREDUKTASE (BVR) UND BVR-ABGELEITETEN PEPTIDEN

Title (fr)

PROCÉDÉS DE MODIFICATION DE SIGNALISATION D'INSULINE UTILISANT LA BILIVERDINE RÉDUCTASE (BVR) ET DES PEPTIDES DÉRIVÉS DE BVR

Publication

EP 2658567 A4 20140924 (EN)

Application

EP 11853575 A 20111228

Priority

• US 201061427652 P 20101228
• US 2011067535 W 20111228

Abstract (en)

[origin: WO2012092341A1] The present invention relates to a method of modulating insulin signaling in a cell. This method involves modifying the nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, in a cell, whereby a change in nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, modulates insulin signaling in the cell via biliverdin reductase interaction with one or both of insulin receptor kinase domain and insulin receptor substrate. Also disclosed are methods of treating a condition associated with insulin signaling and treating a patient for a condition associated with insulin- mediated glucose uptake.

IPC 8 full level

A61K 38/44 (2006.01); A61K 38/28 (2006.01); A61P 3/10 (2006.01)

CPC (source: EP US)

A61K 38/28 (2013.01 - EP US); A61K 38/44 (2013.01 - EP US); A61P 3/10 (2017.12 - EP); C12Y 103/01024 (2013.01 - EP US)

Citation (search report)

• [Y] MAINES MAHIN D: "CRITICAL FUNCTIONS OF HUMAN BILIVERDIN REDUCTASE IN INSULIN/IGF-1 AND MAPK SIGNALING: POTENTIAL APPLICATIONS IN TREATMENT OF DIABETES AND CANCER", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 28, no. 5C, 1 September 2008 (2008-09-01), pages 3393 - 3394, XP009179354, ISSN: 0250-7005
• [Y] MIRALEM T ET AL: "Human biliverdin reductase suppresses goodpasture antigen-binding protein (GPBP) kinase activity: The reductase regulates tumor necrosis factor-[alpha]-NF-[kappa]B-dependent GPBP expression", JOURNAL OF BIOLOGICAL CHEMISTRY 20100423 AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY INC. USA, vol. 285, no. 17, 23 April 2010 (2010-04-23), pages 12551 - 12558, XP002727962, ISSN: 0021-9258
• [Y] LERNER-MARMAROSH NICOLE ET AL: "Regulation of TNF-alpha-activated PKC-zeta signaling by the human biliverdin reductase: identification of activating and inhibitory domains of the reductase", FASEB JOURNAL, vol. 21, no. 14, December 2007 (2007-12-01), pages 3949 - 3962, XP002727963, ISSN: 0892-6638
• [YP] DING BO ET AL: "The coordinated increased expression of biliverdin reductase and heme oxygenase-2 promotes cardiomyocyte survival: a reductase-based peptide counters beta-adrenergic receptor ligand-mediated cardiac dysfunction", FASEB JOURNAL, vol. 25, no. 1, January 2011 (2011-01-01), pages 301 - 313, XP002727964, ISSN: 0892-6638
• [Y] WU B ET AL: "Old biliverdin reductase: Links to insulin resistance and may be a novel therapeutic target", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 71, no. 1, 1 January 2008 (2008-01-01), pages 73 - 76, XP022675775, ISSN: 0306-9877, [retrieved on 20080418], DOI: 10.1016/J.MEHY.2008.02.007
• [T] GIBBS P E M ET AL: "Human biliverdin reductase-based peptides activate and inhibit glucose uptake through direct interaction with the kinase domain of insulin receptor", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, US, vol. 28, no. 6, 1 June 2014 (2014-06-01), pages 2478 - 2491, XP009179360, ISSN: 0892-6638, DOI: 10.1096/FJ.13-247015
• See references of WO 2012092341A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2012092341 A1 20120705; EP 2658567 A1 20131106; EP 2658567 A4 20140924; US 2013344053 A1 20131226

DOCDB simple family (application)

US 2011067535 W 20111228; EP 11853575 A 20111228; US 201113976825 A 20111228